Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer
Anasse Nounsi,
Joseph Seitlinger,
Charlotte Ponté,
Julien Demiselle,
Ysia Idoux-Gillet,
Erwan Pencreach,
Michèle Beau-Faller,
Véronique Lindner,
Jean-Marc Balloul,
Eric Quemeneur,
Hélène Burckel,
Georges Noël,
Anne Olland,
Florence Fioretti,
Pierre-Emmanuel Falcoz,
Nadia Benkirane-Jessel,
Guoqiang Hua
Affiliations
Anasse Nounsi
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Joseph Seitlinger
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Charlotte Ponté
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Julien Demiselle
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Ysia Idoux-Gillet
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Erwan Pencreach
Department of Biochemistry and Molecular Biology, Strasbourg University Hospital (HUS), 67098 Strasbourg, France
Michèle Beau-Faller
Department of Biochemistry and Molecular Biology, Strasbourg University Hospital (HUS), 67098 Strasbourg, France
Véronique Lindner
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Jean-Marc Balloul
Transgene SA, 400 Boulevard Gonthier d’Andernach—Parc d’Innovation—CS80166, 67405 Illkirch Graffenstaden, France
Eric Quemeneur
Transgene SA, 400 Boulevard Gonthier d’Andernach—Parc d’Innovation—CS80166, 67405 Illkirch Graffenstaden, France
Hélène Burckel
Department of Radiation Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), UNICANCER, 67200 Strasbourg, France
Georges Noël
Department of Radiation Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), UNICANCER, 67200 Strasbourg, France
Anne Olland
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Florence Fioretti
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Pierre-Emmanuel Falcoz
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Nadia Benkirane-Jessel
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Guoqiang Hua
Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Radiation therapy and platinum-based chemotherapy are common treatments for lung cancer patients. Several factors are considered for the low overall survival rate of lung cancer, such as the patient’s physical state and the complex heterogeneity of the tumor, which leads to resistance to the treatment. Consequently, precision medicines are needed for the patients to improve their survival and their quality of life. Until now, no patient-derived tumoroid model has been reported to predict the efficiency of radiation therapy in non-small-cell lung cancer. Using our patient-derived tumoroid model, we report that this model could be used to evaluate the efficiency of radiation therapy and cisplatin-based chemotherapy in non-small-cell lung cancer. In addition, these results can be correlated to clinical outcomes of patients, indicating that this patient-derived tumoroid model can predict the response to radiotherapy and chemotherapy in non-small-cell lung cancer.
